Tofacitinib vs TNFi for RA: Safety Study Results Announced
The randomized phase 3b/4 ORAL Surveillance study included 4362 RA patients who were taking methotrexate without adequate control of symptoms.
Cardiovascular Disease
Study Reveals Previously Unknown Drug-Associated Arrhythmias
To identify medications with potential proarrhythmic association.
MPR Weekly Dose Podcast Episode 65
On this week’s MPR pod we take a look at the current status of Johnson & Johnson’s COVID-19 vaccine candidate; Considerations in assessing blood donors during pandemic times; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.
Chlorthalidone Compared With HCTZ for MACE Reduction
To compare the clinical benefits of these diuretics, the study authors conducted a literature search that reported on outcomes such as MACE and left ventricular mass.
Verquvo Approved for Heart Failure with Reduced Ejection Fraction
The approval was based on data from the double-blind, placebo-controlled phase 3 VICTORIA trial.
Narsoplimab Under Review for Stem Cell Transplant-Associated Thrombotic Microangiopathy
The FDA has accepted for filing and granted Priority Review to narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
First Treatment for Newly Diagnosed Light Chain Amyloidosis Approved
The approval was based on data from the open-label, active-controlled phase 3 ANDROMEDA study.
Latest Health Technology at CES 2021
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
Hydroxychloroquine Level Tied to Thrombosis Risk in Lupus
Rate of thrombotic events lower for patients with mean HCQ blood levels >1,068 versus <648 ng/mL
Lower Risk of CKD Stage Progression Found With Apixaban
Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
